Semaglutide and Cardiovascular Risk: What a 2026 Meta-Analysis Shows
A 2026 meta-analysis found 32% lower odds of major cardiovascular events with semaglutide, reinforcing cardiovascular benefit while emphasizing baseline risk, evidence limits, and indication-specific interpretation.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.